|
KO |
CRISPR-Cas system
|
|
|
Restriction and modification system (R-M system)
|
|
|
Toxin-antitoxin system (TA system)
|
Type I TA system
|
Type II TA system
|
MazF-MazE
|
ChpB-ChpS
|
YhaV-PrlF
|
RelE/StbE-RelB/StbD
|
YafQ-dinJ
|
YoeB-YefM
|
HipA-HipB
|
HicA-HicB
|
YafO-YafN
|
Hha-TomB
|
PspC-PspB
|
CcdB-CcdA
|
ParE-ParD
|
Doc-Phd
|
HigB-HigA
|
MqsR-MqsA
|
VapC-VapB
|
PezT-PezA
|
YobL-YobK
|
YokI-YokJ
|
YqcG-YqcF
|
YxiD-YxxD
|
FitB-FitA
|
BC_0920-BC_0921
|
Type II TA system related factors
|
Rv2150c ftsZ; cell division protein FtsZ
Rv2992c gltS; glutamate--tRNA ligase
|
K03531 ftsZ; cell division protein FtsZ
K01885 EARS; glutamyl-tRNA synthetase [EC:6.1.1.17]
|
Type III TA system
|
Type IV TA system
|
Type V TA system
|
|
|
DNA phosphothiolation system
|